INNOVATE Corp. 8-K

What Happened
INNOVATE Corp. (VATE) filed a Form 8-K on February 10, 2026 reporting that it issued a press release announcing its transdermal GFR article was recognized as one of five 2025 Editors’ Choice articles by the Journal of the American Society of Nephrology (JASN). The press release is attached to the 8-K as Exhibit 99.1.

Key Details

• The 8-K was filed on February 10, 2026 and cites a press release titled “Transdermal GFR Article Recognized as One of Five 2025 Editors’ Choice Articles by Journal of the American Society of Nephrology (JASN).”
• Exhibit 99.1 contains the press release; the company states the exhibit “shall not be deemed filed” for purposes of Section 18 of the Exchange Act or incorporated by reference except as expressly set forth.
• The report is signed by Michael J. Sena, Chief Financial Officer, on behalf of INNOVATE Corp.

Why It Matters
This disclosure highlights third‑party recognition of INNOVATE’s transdermal GFR research by a leading nephrology journal (JASN), which can support the company’s scientific credibility and visibility in the medical community. For investors, the announcement is a non‑financial, reputational milestone rather than a change in operations or financial results; no earnings, management changes, or transaction details were reported in this filing.